Recombinant Anti-NRAS (mutated Q61R) antibody [SP174] (ab227658)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [SP174] to NRAS (mutated Q61R)
- Suitable for: Flow Cyt, WB, IHC-P
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-NRAS (mutated Q61R) antibody [SP174]
See all NRAS primary antibodies -
Description
Rabbit monoclonal [SP174] to NRAS (mutated Q61R) -
Host species
Rabbit -
Specificity
The immunogen used for this product shares 91% homology with KRAS and HRAS. Cross-reactivity with these proteins has not been confirmed experimentally.
-
Tested applications
Suitable for: Flow Cyt, WB, IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: SK-MEL-2 cell lysate. IHC-P: Human skin melanoma tissue. Flow Cyt: SK-MEL-2
-
General notes
This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.60
Preservative: 0.1% Sodium azide
Constituents: PBS, 1% BSA -
Concentration information loading...
-
Purity
Protein A/G purified -
Purification notes
Purified from TCS by protein A/G. -
Clonality
Monoclonal -
Clone number
SP174 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab227658 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt |
1/2000.
|
|
WB | (1) |
1/400. Predicted molecular weight: 21 kDa.
|
IHC-P | (1) |
1/100.
Perform heat mediated antigen retrieval with EDTA buffer pH 8.0 before commencing with IHC staining protocol. |
Notes |
---|
Flow Cyt
1/2000. |
WB
1/400. Predicted molecular weight: 21 kDa. |
IHC-P
1/100. Perform heat mediated antigen retrieval with EDTA buffer pH 8.0 before commencing with IHC staining protocol. |
Target
-
Function
Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. -
Involvement in disease
Defects in NRAS are a cause of juvenile myelomonocytic leukemia (JMML) [MIM:607785]. JMML is a pediatric myelodysplastic syndrome that constitutes approximately 30% of childhood cases of myelodysplastic syndrome (MDS) and 2% of leukemia.
Defects in NRAS are the cause of Noonan syndrome type 6 (NS6) [MIM:613224]. A syndrome characterized by facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears. Other features can include short stature, a short neck with webbing or redundancy of skin, cardiac anomalies, deafness, motor delay and variable intellectual deficits. -
Sequence similarities
Belongs to the small GTPase superfamily. Ras family. -
Post-translational
modificationsPalmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi. -
Cellular localization
Cell membrane. Golgi apparatus membrane. Shuttles between the plasma membrane and the Golgi apparatus. - Information by UniProt
-
Database links
- Entrez Gene: 4893 Human
- Omim: 164790 Human
- SwissProt: P01111 Human
- Unigene: 486502 Human
-
Alternative names
- ALPS4 antibody
- AV095280 antibody
- GTPase NRas antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NRAS (mutated Q61R) antibody [SP174] (ab227658)This image is courtesy of an anonymous collaborator.
Immunohistochemical analysis of paraffin-embedded human primary malignant melanoma tissue (mutation status: NRAS Q61R) labeling NRAS with ab227658 at 1/100 dilution for 30 min at RT. The tissue was counterstained with Hematoxylin. Heat mediated antigen retrieval was achieved by using EDTA buffer pH 9.0 before IHC staining.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NRAS (mutated Q61R) antibody [SP174] (ab227658)This image is courtesy of an anonymous collaborator.
Immunohistochemical analysis of paraffin-embedded human primary malignant melanoma tissue (mutation status: NRAS Q61R) labeling NRAS with ab227658 at 1/100 dilution for 30 min at RT. The tissue was counterstained with Hematoxylin. Heat mediated antigen retrieval was achieved by using EDTA buffer pH 9.0 before IHC staining.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NRAS (mutated Q61R) antibody [SP174] (ab227658)This image is courtesy of an anonymous collaborator.
Immunohistochemical analysis of paraffin-embedded human primary malignant melanoma tissue (mutation status: NRAS Q61R) labeling NRAS with ab227658 at 1/100 dilution for 30 min at RT. The tissue was counterstained with Hematoxylin. Heat mediated antigen retrieval was achieved by using EDTA buffer pH 9.0 before IHC staining.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NRAS (mutated Q61R) antibody [SP174] (ab227658)This image is courtesy of an anonymous collaborator.
Immunohistochemical analysis of paraffin-embedded human metastatic malignant melanoma tissue (mutation status: NRAS Q61) labeling NRAS with ab227658 at 1/100 dilution for 30 min at RT. The tissue was counterstained with Hematoxylin. Heat mediated antigen retrieval was achieved by using EDTA buffer pH 9.0 before IHC staining.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NRAS (mutated Q61R) antibody [SP174] (ab227658)This image is courtesy of an anonymous collaborator.
Immunohistochemical analysis of paraffin-embedded human metastatic malignant melanoma tissue (mutation status: NRAS Q61K) labeling NRAS with ab227658 at 1/100 dilution for 30 min at RT. The tissue was counterstained with Hematoxylin. Heat mediated antigen retrieval was achieved by using EDTA buffer pH 9.0 before IHC staining.
-
Flow Cytometry analysis of SK-MEL-2( Human skin malignant melanoma) cells labeling NRAS with purifiedab227658 at 1:200 dilution (0.8 µg/ml) (Red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti rabbit IgG (Alexa Fluor© 488, ab150077) secondary antibody was used at 1:2000 dilution. Isotype control - Rabbit monoclonal IgG (ab172730) / Black. Unlabeled control - Unlabelled cells / blue.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-NRAS (mutated Q61R) antibody [SP174] (ab227658)
IHC image of NRAS (mutated Q61R) staining in a section of formalin-fixed paraffin-embedded human skin melanoma* performed on a Leica BONDTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with EDTA buffer (pH9, epitope retrieval solution 2) for 20mins. The section was then incubated with ab227658, 1/100 dilution, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset secondary-only control image is taken from an identical assay without primary antibody.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
-
Anti-NRAS (mutated Q61R) antibody [SP174] (ab227658) at 1/400 dilution + SK-MEL-2 cell lysate
Predicted band size: 21 kDa
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (8)
ab227658 has been referenced in 8 publications.
- Pareja F et al. Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas. Histopathology 76:865-874 (2020). PubMed: 31887226
- Pellegrini C et al. Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis. J Mol Diagn 20:110-122 (2018). PubMed: 29061376
- Manevitz-Mendelson E et al. Somatic NRAS mutation in patient with generalized lymphatic anomaly. Angiogenesis N/A:N/A (2018). PubMed: 29397482
- Turchini J et al. NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRASQ61R or KRASQ61R Mutation in Colorectal Carcinoma. Appl Immunohistochem Mol Morphol 25:475-480 (2017). PubMed: 26862952
- Dias-Santagata D et al. KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas. Br J Dermatol 177:1376-1384 (2017). PubMed: 28734009
- Mourah S et al. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis. Eur Respir J 47:1785-96 (2016). PubMed: 27076591
- Kakavand H et al. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Histopathology 69:680-6 (2016). PubMed: 27151331
- Dias-Santagata D et al. Immunohistochemical Detection of NRASQ61R Mutation in Diverse Tumor Types. Am J Clin Pathol 145:29-34 (2016). PubMed: 26712868